Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

Six Things to Watch for at the JP Morgan Healthcare Conference
BioSpace
Fri, 01/4/19 - 10:35 am
Tags:
Moderna Therapeutics, Sarepta Therapeutics, Biogen, Gilead Sciences, Bluebird Bio
For CAR-T Cancer Fighters in the Real World, Two Roads Diverge
Xconomy
Thu, 01/3/19 - 04:16 pm
Tags:
cancer, CAR-T, Gilead Sciences, Yescarta, Novartis, Kymriah
Gilead Ends Year With Two Major Deals That Could Total More Than $3.125 Billion
BioSpace
Thu, 12/20/18 - 12:12 pm
Tags:
Gilead Sciences, Agenus, Scholar Rock, immuno-oncology
Gilead dangles $105M in quick cash to sign Scholar Rock to a discovery deal for its growing NASH pipeline
Endpoints
Wed, 12/19/18 - 10:39 am
Tags:
Gilead Sciences, NASH, Scholar Rock
2 Sets of Disasters Biotech Will Pay For in 2019
Yahoo/Motley Fool
Mon, 12/17/18 - 12:16 am
Tags:
Gilead Sciences, Yescarta, Novartis, Kymriah, Spark Therapeutics, Luxturna
Lessons From The Biggest Pharma Drug Launches Of All Time
Forbes
Tue, 12/11/18 - 10:26 am
Tags:
drug launches, Gilead Sciences, JNJ, Pfizer
Gilead Taps Roche Veteran Daniel O’Day as New CEO
BioSpace
Mon, 12/10/18 - 11:58 am
Tags:
Gilead Sciences, Pharma CEOs, Roche, Daniel O'Day
Did Gilead Sciences Make an $11 Billion Blunder?
Motley Fool
Sun, 12/9/18 - 03:53 pm
Tags:
Gilead Sciences, Pharmasset, hepatitis C
CEO of Chapel Hill firm talks 2 new partnerships with big pharma
Bizjournals
Sat, 12/8/18 - 10:31 am
Tags:
Target PharmaSolutions, Gilead Sciences, Bristol-Myers Squibb, hepatitis B, NASH
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
Endpoints
Thu, 12/6/18 - 10:02 am
Tags:
Genfit, NASH, Gilead Sciences, Intercept Pharma, clinical trials, elafibranor
What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs
Endpoints
Wed, 12/5/18 - 11:32 am
Tags:
Takeda, Gilead Sciences, Martin Shkreli, drug pricing
China approves Descovy, Harvoni, Hemlibra
BioCentury
Tue, 12/4/18 - 11:51 pm
Tags:
China, Harvoni, Descovy, Hemlibra, Roche, Gilead Sciences
Gilead can now attempt at takeover of Galapagos
GoinPharma
Sat, 12/1/18 - 12:22 pm
Tags:
Gilead Sciences, Galapagos, M&A
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Biopharma Dive
Mon, 11/26/18 - 11:13 pm
Tags:
Gilead Sciences, Galapagos, JAK inhibitors, rheumatoid arthritis, filgotinib
Are Gilead or Roche Interested in Buying Tesaro? Company Rumored to be on the Market
BioSpace
Mon, 11/19/18 - 11:25 am
Tags:
Tesaro, Roche, Gilead Sciences, M&A
Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis
Pharmaceutical Business Review
Mon, 11/12/18 - 09:24 am
Tags:
Gilead Sciences, GS-9674, primary sclerosing cholangitis, clinical trials
NASH drugs come into focus as field awaits late-stage data
BioSpace
Sat, 11/10/18 - 12:43 pm
Tags:
NASH, Intercept Pharma, Gilead Sciences, Genfit, Allergan
Gilead's search for the next great liver drug won't end with its FXR agonist
Biopharma Dive
Sat, 11/10/18 - 12:01 pm
Tags:
Gilead Sciences, liver disease, GS-9674
Galapagos CEO says a sale to Gilead is 50% likely
GoinPharma
Mon, 11/5/18 - 11:50 am
Tags:
Galapagos, M&A, Gilead Sciences
Gilead Sciences and Tango Therapeutics Form Partnership Worth Up to $1.7 Billion to Develop Next-Gen Immuno-Oncology Therapies
CP Wire
Wed, 10/31/18 - 09:45 am
Tags:
Gilead Sciences, Tango Therapeutics, cancer immunotherapy

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.